1617 MMEDB283 TP1 etudiant

!!"#$%&'()(*+,-./01,2.+(304(5,3,25,26075(89/213:75(;(<-3=304(>-3,26075(
%?@AB%?@C( ( (
@(
!"#$%#&#'())*+,#-+#,./01+#
2()3+43+#5*-1678#
D+7(9602>7(/7(1E7-1E70-5(5F2+,7--.G7(50-(:3(50-=27(/7(>3,27+,5(3,,72+,5(/F0+(,H>7(/7(13+17-(
7,(,-32,95(>3-(-3/2.,E9-3>27I(*:5(5.0E32,7-327+,(/91-2-7(:3(50-=27(>.5,(,-32,787+,(/7(175(
>3,27+,5(57:.+(:7(J32,(60F2:5(327+,(K27+(-9>.+/0(.0(+.+(30(,-32,787+,(>3-(-3/2.,E9-3>27I(
(
"+(1.+50:,3+,(:75(/.++975(/0(513++7-(50-(:F9=.:0,2.+(/7(:F31,2=2,9(,08.-3:7(7+,-7(:7(/9K0,(7,(
:3(J2+(/7(:3(-3/2.,E9-3>27L(:75(89/712+5(.+,(1:3559(:75(>3,27+,5(57:.+(60F2:5(.+,(K27+(-9>.+/0(
M/282+0,2.+(28>.-,3+,7(/7(:F31,2=2,9(,08.-3:7(3>-N5(-3/2.,E9-3>27O(.0(+.+(M/282+0,2.+(
J32K:7O(30(,-32,787+,I(*:5(+.,7+,(9G3:787+,(>.0-(1E3607(>3,27+,(:3(/7-+2N-7(2+J.-83,2.+(
/25>.+2K:7(1.+17-+3+,(5.+(9,3,(M7+1.-7(7+(=27(.0(/919/9OI(
(
P(>3-,2-(/7(175(2+J.-83,2.+5(M-7>-2575(/3+5(:7(,3K:730(@OL(2:5(1E7-1E7+,(Q(,-317-(:F9=.:0,2.+(/7(
:3(50-=27(/7(175(/704(G-.0>75(/7(>3,27+,5I((
9.+,31(),#-+#:7,+#
% ;0(8.31()#-+#87#,./01+#7.#6(./,#-.#3+5<,#
%=% '7),#6>76.)#-+,#?/(.<+,#-+#<731+)3@#3/76+A#8B*0(8.31()#-+#87#,./01+#7.#6(./,#-.#3+5<,#
+)#.3181,7)3#8+,#-+.4#5*3>(-+,#,.107)3+,#&#C./01+#-1/+63+@#5*3>(-+#-+#D7<87)EF+1+/#
%=G "7/51#6+,#5*3>(-+,@#87H.+88+#</+)-#+)#6(5<3+#8+,#-())*+,#6+),./*+,#I#
%=J '*6/10+A#8B*0(8.31()#-+#87#,./01+#+)#K()631()#-+#87#/*<(),+#7.#3/713+5+)3#
G C./01+#,+8()#8+#5(-L8+#+4<()+)31+8#
G=% 2786.8+A#8+#/1,H.+#5(M+)#-+#-*6L,#<7/#5(1,%#-7),#6>76.)#-+,#?/(.<+,#
G=G 2786.8+A#8B*0(8.31()#-+#87#,./01+#7.#6(./,#-.#3+5<,#+)#.3181,7)3#6+#/1,H.+##
G=J !/76+A#87#6(./:+#-B*0(8.31()#-+#87#,./01+#7.#6(./,#-.#3+5<,#,.107)3#6+#5(-L8+#
9.+,31(),#707)6*+,#
J N)K*/+)6+#,3731,31H.+#
J=% OE3E()#,.KK1,755+)3#-B1)K(/5731()#<(./#/+P+3+/#8B>M<(3>L,+#,+8()#87H.+88+#87#,./01+#+,3#
87#5Q5+#H.+88+#H.+#,(13#87#/*<(),+#7.#3/713+5+)3#-+#/7-1(3>*/7<1+#I#
R 9.+,31(),#-+#/*K8+41()#
R=% S7#-151).31()#-+#8B7631013*#3.5(/78+#+,3E+88+#87#67.,+#-+#87#5+188+./+#,./01+#I#
R=G "+.3E()#.3181,+/#8+#K713#H.+#8+#<731+)3#713#/*<()-.#(.#)()#7.#3/713+5+)3#<(./#
</()(,31H.+/#,7#,./01+#-7),#8+,#</(6>71),#5(1,#I#
(#
((((((((((((((((((((((((((((((((((((((((((((((((((((((((
@(R25607(2+5,3+,3+9(/7(/91N5(

!!"#$%&'()(*+,-./01,2.+(304(5,3,25,26075(89/213:75(;(<-3=304(>-3,26075(
%?@AB%?@C( ( (
%(
R=J #
(
Tableau'1:'Temps&de&survie&de&patients&atteints&d'un&cancer&et&traité&par&radiothérapie&selon&l'évolution&de&l'activité&
tumorale&durant&le&traitement.'Les'temps'de'survie'des'patients'qui'ne'sont'pas'encore'décédés'(exclus'vivants)'ou'qui'ont'
été'perdus'de'vue'sont'indiqués'avec'le'signe'«'>'».'Exemple':'Le'patient'n°2'a'survécu'au'moins'5'mois'après'la'fin'du'
traitement'de'radiothérapie.'
diminution importante
diminution faible ou nulle
Patient n°
Temps de survie (mois)
Patient n°
Temps de survie (mois)
1
3
28
> 4
2
> 5
29
> 4
3
> 12
30
6
4
> 12
31
7
5
> 12
32
9
6
21
33
9
7
> 27
34
11
8
> 30
35
> 13
9
> 33
36
> 15
10
> 35
37
15
11
> 36
38
> 19
12
> 44
39
24
13
> 45
40
24
14
> 45
41
> 33
15
> 49
42
> 34
16
> 50
43
> 37
17
> 51
44
> 37
18
> 51
45
> 53
19
> 55
46
> 62
20
> 60
47
> 66
21
> 61
48
> 67
22
> 63
49
> 73
23
> 64
50
> 74
24
> 66
51
> 78
25
> 73
52
> 78
26
> 76
53
> 78
27
> 84
54
> 84
55
> 88
56
> 89
57
> 92
(
(